Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Can ovarian function be protected in young women receiving chemotherapy?

Nature Clinical Practice Oncology volume 3, pages 532–533 (2006)Cite this article

boxed-textRecchia F et al. (2006) Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 106: 514–523

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Jemel A et al. (2004) American Cancer Society. Cancer statistics, 2004. CA Cancer J Clin 54: 8–29

    Article  Google Scholar 

  2. Castiglione-Gertsch M et al. (2003) Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 95: 1833–1846

    Article  Google Scholar 

  3. Stern CJ et al. (2006) Fertility preservation in female oncology patients. Aust N Z J Obstet Gynaecol 46: 15–23

    Article  Google Scholar 

  4. Blumenfeld Z and Eckman A (2005) Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a. J Natl Cancer Inst Monogr 34: 40–43

    Article  CAS  Google Scholar 

  5. Kaufmann M et al. (2003) Survival analyses from the ZEBRA study. Goserelin (Zoladex®) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 39: 1711–1717

    Article  CAS  Google Scholar 

  6. International Breast Cancer Study Group (2001) Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: is chemotherapy necessary for premenopausal women with node-positive, endocrine responsive breast cancer? First results of International Breast Cancer Study Group Trial 11–93. The Breast 10 (Suppl 3): 130–138

  7. Sklar C (2005) Maintenance of ovarian function and risk of premature menopause related to cancer treatment. J Natl Cancer Inst Monogr 34: 25–27

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Center for Fertility and Reproductive Medicine at Cedars-Sinai Medical Center,

    Margareta D Pisarska & Lee-Chuan Kao

  2. David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

    Margareta D Pisarska & Lee-Chuan Kao

Authors
  1. Margareta D Pisarska
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lee-Chuan Kao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Margareta D Pisarska.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pisarska, M., Kao, LC. Can ovarian function be protected in young women receiving chemotherapy?. Nat Rev Clin Oncol 3, 532–533 (2006). https://doi.org/10.1038/ncponc0592

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0592

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing